
Vineti sets a collaboration with Quick for CGT logistics
Better data-sharing for cellular and genetic therapies is the goal
Having established
Cellular and genetic therapies (CGTs), such as those involving CAR-T technology, usually involve extracting cells from a patient, conveying it to a facility where the genetic manipulations are performed, and then returning it to the patient for infusion. “CGTs represent the time that GMP-based processes originate in the clinic,” notes DuRoss. “Our value proposition is to provide a system of record for the entire process.”
Quick and Vineti accompanied the partnership announcement with release of a “tip sheet” for managing CGT processes, available at the Vineti
Newsletter
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.